NCT07129551Recruiting
Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery
Source: ClinicalTrials.gov · Last updated 12 Jan 2026
Brief summary (registry, in English)
As part of a feasibility study, it's planned to use a 3D virtual mixed reality model with prostate cancer patients who show signs of lymph node metastasis and are scheduled for surgery. The model is based on PSMA PET imaging performed prior to surgery and will be evaluated by surgeons, the surgical team, and patients as part of the consultation process. First, the researcher investigates whether the removal of lymph node metastases has improved compared to the data in the literature . In addition, the study examines how the 3D model influences the movement of surgical instruments and the efficiency of surgical removal of lymph node metastases. To this end, the analyzed recorded video and position data of the instruments used during procedures performed with a surgical robot. It's also an aim to develop two methods-using landmarks and visual position tracking-for more targeted navigation during surgery. Additionally, short-term results examine, such as PSA response rates, as an indication of successful lymph node metastasis removal and patient quality of life.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- First submitted
- 5 Aug 2025
- Start date
- 21 Jan 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Martini-Klinik am UKE GmbH
- Diseases
- Prostate cancer
- NCT number
- NCT07129551
What you commit to
- Study type: Interventional
- Planned participants: 102
- From 21 Jan 2026 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- contraindication for surgical intervention
- androgen deprivation therapy (ADT) within the last 3 months
Age
- Estimated life expectancy \<10 years
Who the study is looking for
- Cohort A:
- Patients with hormone-sensitive prostate cancer scheduled for radical prostatectomy with pelvic lymph node dissection
- \<3 PSMA-PET-avid lymph node metastases (PSMA expression score \>2) in the pelvis.
- Cohort B:
- Patients with hormone-sensitive recurrent prostate cancer after radical prostatectomy with planned pelvic salvage lymph node dissection
- \<3 PSMA-PET-avid lymph node metastases (PSMA expression score \>2) in the pelvis
- PSA value \<2ng/ml.
Age in the registry: 18 years to 78 years · Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Anke Renter Coordinator of this site? Confirm its status | Hamburg | Germany | Not yet recruiting |
| Martini Klinik Coordinator of this site? Confirm its status | Hamburg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.